Anti-programmed cell death receptor 1 (PD-1) immunotherapy aims to block the interaction of tumor-reactive T cells with PD-1 ligands (PD-L1 and PD-L2), which are expressed on numerous cell types, such as leukocytes and the tumor cells themselves, resulting in T-cell inactivation.1 2. Here, CD274 is linked to neoplasm.